Receptos Files Registration Statement for Proposed Initial Public Offering
Receptos Files Registration Statement for Proposed Initial Public Offering
SAN DIEGO, April 4, 2013 /PRNewswire/ -- Receptos, Inc., a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it has filed a registration statement on Form S-1 with the U.S.
T2 Biosystems Announces Issuance of Patent Covering T2Candida®Assay
T2 Biosystems Announces Issuance of Patent Covering T2Candida®Assay
--T2 Bio Continues to Expand Intellectual Property Portfolio Covering T2MR® Technology and Assays--
Agios Publishes Two Articles in Science Demonstrating the Effects of Mutant IDH1 and IDH2 Inhibitors in Primary Tumor Models
Agios Publishes Two Articles in Science Demonstrating the Effects of Mutant IDH1 and IDH2 Inhibitors in Primary Tumor Models
IDH1 and IDH2 Mutant Inhibitors Reverse Differentiation Blocks in Patient-Derived Tumor Samples
Foundation Medicine and Agios Announce Diagnostic Discovery Collaboration for IDH1 and IDH2 Cancer Metabolism Programs
Foundation Medicine and Agios Announce Diagnostic Discovery Collaboration for IDH1 and IDH2 Cancer Metabolism Programs
CAMBRIDGE, MASS. – April 4, 2013 – Foundation Medicine, Inc., and Agios Pharmaceuticals, Inc., today announced a multi-year diagnostic partnership for Agios’ lead programs in cancer metabolism. These programs focus on developing new cancer metabolism inhibitors targeting tumors carrying mutations in either the IDH1 or IDH2 metabolic enzymes.
BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins™
BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins™
BIND Eligible to Receive Approximately $50 Million in Upfront and Development Milestone Payments Plus Additional Regulatory and Sales Milestones and Royalties for Each Accurin
Seventh Sense Biosystems Announces Initiation of Registration Trial for Painless TAP™ Blood Collection Device
Seventh Sense Biosystems Announces Initiation of Registration Trial for Painless TAP™ Blood Collection Device
Company Anticipates Filing for Regulatory Approval in 2Q 2013
TARIS Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate
TARIS Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate
LEXINGTON, Mass., Apr 02, 2013 (BUSINESS WIRE) -- TARIS Biomedical(R), a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has raised an additional $12.5 million financing round through its existing investors, Flagship Ventures, Flybridge Capital Partners, Polaris Partners and Third Rock Ventures. Including this round, TARIS(R) has raised a total of $49.8M.
Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
BILLERICA, Mass., April 1, 2013 /PRNewswire/ --Seahorse Bioscience, the world leader in instruments and assay kits for measuring cell metabolism recently launched the XF Plasma Membrane Permeabilizer (PMP), a reagent that enables scientists to measure the biochemistry and mechanisms of mitochondrial dysfunction, without the need for mitochondrial isolation or detergent-based permeabilization methods.
T2 Biosystems Completes $40 Million Series E Financing to Support Clinical Programs and Commercialization of Sepsis Diagnostics
T2 Biosystems Completes $40 Million Series E Financing to Support Clinical Programs and Commercialization of Sepsis Diagnostics
--Highly Sensitive and Rapid Identification of Candida Species Directly from Whole Blood in Approximately Three Hours--
LEXINGTON, Mass.--(BUSINESS WIRE)--
Acceleron Receives Two FDA Orphan Designations for ACE-536
Acceleron Receives Two FDA Orphan Designations for ACE-536
ACE-536 granted rare disease designation for the treatment of beta-thalassemia and for the treatment of myelodysplastic syndromes (MDS)